OVERVIEW

Strategies to Address Immunotherapy Failure in Metastatic Urothelial Cancer is organized by Prime Education LLC.

Dates:
Release Date: November 15, 2019
Expiration Date: November 14, 2020

Accreditation:
• 1.0 CME/CE for Physicians (ACCME)
• 1.0 CPE for Pharmacists (ACPE + NABP)
• 1.0 CNE for Nurses (ANCC)

Activity Overview:
While immunotherapy has revolutionized care for metastatic urothelial cancer, it doesn't work for everyone. Patients who progress with or fail immunotherapy will need subsequent therapy, and there is limited data to guide treatment selection. New data from late-stage clinical trials introduce emerging targeted agents with great promise in improving outcomes for these patients.

Don't miss this informative webcast, where experts in bladder cancer and managed care discuss:
• Current strategies for evidence-based treatment decision-making for heavily pretreated patients
• Biomarkers that may improve therapy selection
• The latest clinical evidence supporting novel agents for the treatment of metastatic urothelial cancer

Learning Objectives:
• Evaluate challenges and barriers to treatment and management of patients with metastatic urothelial cancer following immune checkpoint inhibitors
• Assess clinical evidence for emerging targeted agents as therapeutic options for patients unresponsive to or progressing on immunotherapies
• Integrate managed care considerations for novel agents based on efficacy and safety data and the value of biomarkers in therapeutic decision-making

Additional details will be posted as soon as information is available.